$HOWL insider trading
Over the last 12 months, Werewolf Therapeutics insiders reported no purchases and 53 sales totaling $7.8M across SEC Form 4 filings. 94% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $7.8M 53 events
- Events · 12m
- 53 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 94% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | EVNIN LUKED | ▼ Sale | 143,199 | $0.31 | $45K | -100% | plan · 2 tranches · indirect |
| Jun 29, 2026 | EVNIN LUKED | ▼ Sale | 157,084 | $0.3 | $47K | -52.3% | plan · indirect |
| Jun 17, 2026 | RA CAPITAL MANAGEMENT, L.P.10% | ▼ Sale | 416,911 | $0.35 | $146K | -57.9% | 2 tranches · indirect |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.10% | ▼ Sale | 448,836 | $0.39 | $174K | -57.5% | 6 tranches · indirect |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P.10% | ▼ Sale | 678,226 | $0.37 | $254K | -65.2% | 6 tranches · indirect |
| Jun 9, 2026 | EVNIN LUKED | ▼ Sale | 76,928 | $0.37 | $28K | -20.4% | plan · indirect |
| Jun 8, 2026 | EVNIN LUKED | ▼ Sale | 105,565 | $0.41 | $43K | -21.9% | plan · 3 tranches · indirect |
| Jun 3, 2026 | EVNIN LUKED | ▼ Sale | 29,749 | $0.42 | $12K | -5.8% | plan · indirect |
| Jun 2, 2026 | EVNIN LUKED | ▼ Sale | 29,595 | $0.45 | $13K | -5.5% | plan · indirect |
| Jun 1, 2026 | EVNIN LUKED | ▼ Sale | 80,459 | $0.47 | $38K | -12.9% | plan · indirect |
| May 29, 2026 | EVNIN LUKED | ▼ Sale | 32,556 | $0.45 | $15K | -5% | plan · indirect |
| May 28, 2026 | EVNIN LUKED | ▼ Sale | 27,698 | $0.46 | $13K | -4.1% | plan · indirect |
| May 27, 2026 | EVNIN LUKED | ▼ Sale | 80,852 | $0.48 | $39K | -10.6% | plan · indirect |
| May 21, 2026 | EVNIN LUKED | ▼ Sale | 36,387 | $0.42 | $15K | -3.8% | plan · indirect |
| May 7, 2026 | EVNIN LUKED | ▼ Sale | 100,581 | $0.64 | $64K | -6% | plan · 3 tranches · indirect |
| May 4, 2026 | EVNIN LUKED | ▼ Sale | 274,619 | $0.72 | $198K | -14.1% | plan · 3 tranches · indirect |
| Apr 29, 2026 | EVNIN LUKED | ▼ Sale | 205,911 | $0.75 | $155K | -9.5% | plan · 3 tranches · indirect |
| Jan 16, 2026 | EVNIN LUKED | ▼ Sale | 38,782 | $0.54 | $21K | -1.8% | plan · indirect |
| Jan 15, 2026 | EVNIN LUKED | ▼ Sale | 111,227 | $0.56 | $62K | -4.8% | plan · 3 tranches · indirect |
| Jan 12, 2026 | EVNIN LUKED | ▼ Sale | 91,374 | $0.59 | $54K | -3.8% | plan · 3 tranches · indirect |
| Jan 7, 2026 | EVNIN LUKED | ▼ Sale | 71,054 | $0.65 | $46K | -2.9% | plan · 3 tranches · indirect |
| Jan 2, 2026 | EVNIN LUKED | ▼ Sale | 78,377 | $0.62 | $48K | -3.1% | plan · 3 tranches · indirect |
| Dec 29, 2025 | EVNIN LUKED | ▼ Sale | 291,283 | $0.64 | $185K | -10.2% | plan · 5 tranches · indirect |
| Dec 17, 2025 | EVNIN LUKED | ▼ Sale | 48,171 | $1.08 | $52K | -1.7% | plan · 3 tranches · indirect |
| Dec 12, 2025 | EVNIN LUKED | ▼ Sale | 82,971 | $1.07 | $89K | -2.8% | plan · 3 tranches · indirect |
| Dec 9, 2025 | EVNIN LUKED | ▼ Sale | 95,179 | $1 | $95K | -3.1% | plan · 3 tranches · indirect |
| Dec 4, 2025 | MPM BioVentures 2014, L.P. | ▼ Sale | 199,732 | $0.92 | $183K | -4% | plan · 3 tranches · indirect |
| Dec 4, 2025 | GADICKE ANSBERT | ▼ Sale | 199,732 | $0.92 | $183K | -4% | plan · 3 tranches · indirect |
| Dec 4, 2025 | EVNIN LUKED | ▼ Sale | 128,185 | $0.92 | $118K | -4% | plan · 3 tranches · indirect |
| Dec 1, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 141,927 | $0.96 | $137K | -2.8% | plan · 3 tranches · indirect |
| Dec 1, 2025 | GADICKE ANSBERT10% | ▼ Sale | 141,927 | $0.96 | $137K | -2.8% | plan · 3 tranches · indirect |
| Dec 1, 2025 | EVNIN LUKED | ▼ Sale | 91,088 | $0.96 | $88K | -2.8% | plan · 3 tranches · indirect |
| Nov 25, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 195,666 | $0.92 | $180K | -3.7% | plan · 3 tranches · indirect |
| Nov 25, 2025 | GADICKE ANSBERT10% | ▼ Sale | 195,666 | $0.92 | $180K | -3.7% | plan · 3 tranches · indirect |
| Nov 25, 2025 | EVNIN LUKED | ▼ Sale | 125,576 | $0.92 | $115K | -3.7% | plan · 3 tranches · indirect |
| Nov 20, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 160,103 | $0.92 | $148K | -2.9% | plan · 3 tranches · indirect |
| Nov 20, 2025 | GADICKE ANSBERT10% | ▼ Sale | 160,103 | $0.92 | $148K | -2.9% | plan · 3 tranches · indirect |
| Nov 20, 2025 | EVNIN LUKED | ▼ Sale | 102,753 | $0.92 | $95K | -2.9% | plan · 3 tranches · indirect |
| Nov 17, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 209,652 | $0.96 | $201K | -3.7% | plan · 3 tranches · indirect |
| Nov 17, 2025 | GADICKE ANSBERT10% | ▼ Sale | 209,652 | $0.96 | $201K | -3.7% | plan · 3 tranches · indirect |
| Nov 17, 2025 | EVNIN LUKED | ▼ Sale | 134,553 | $0.96 | $129K | -3.7% | plan · 3 tranches · indirect |
| Nov 12, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 213,529 | $1.13 | $241K | -3.6% | plan · 4 tranches · indirect |
| Nov 12, 2025 | GADICKE ANSBERT10% | ▼ Sale | 213,529 | $1.13 | $241K | -3.6% | plan · 4 tranches · indirect |
| Nov 12, 2025 | EVNIN LUKED | ▼ Sale | 137,041 | $1.13 | $155K | -3.6% | plan · 4 tranches · indirect |
| Nov 6, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 242,890 | $1.22 | $296K | -4% | plan · 3 tranches · indirect |
| Nov 6, 2025 | GADICKE ANSBERT10% | ▼ Sale | 242,890 | $1.22 | $296K | -4% | plan · 3 tranches · indirect |
| Nov 6, 2025 | EVNIN LUKED | ▼ Sale | 155,885 | $1.22 | $190K | -4% | plan · 3 tranches · indirect |
| Nov 3, 2025 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 295,043 | $1.33 | $392K | -4.6% | plan · 3 tranches · indirect |
| Nov 3, 2025 | GADICKE ANSBERT10% | ▼ Sale | 295,043 | $1.33 | $392K | -4.6% | plan · 3 tranches · indirect |
| Nov 3, 2025 | EVNIN LUKED | ▼ Sale | 189,356 | $1.33 | $251K | -4.6% | plan · 3 tranches · indirect |
Every $HOWL filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Werewolf Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $HOWL feed.